Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I will!
Anyone called RNS tomorrow yet...
The Global Co "severely slowed by Covid" comment raised in Digittt's update following his conversation with PHC this morning, may give some leaning toward EL as Global co and the credence of what they are saying re progress.
As of 12th April EL's solo Covid-19 antibody has been stopped because it could not match ..against emerging coronovirus variants. The "feds" had stopped using it in several states and now EL have pulled its supply of bamianivimab as a solo therapy in the US altogether. The FDA have ordered greater monitoring of the Lilly / Regeneron authorized drugs against emerging variants. I am sure that if anything is slowing progress as indicated to Digittt it will be detailed scrutiny and insistence on greater monitoring ordered by the FDA. T
Whilst I am sure Covid has slowed lots of progress, the above may slow things a whole lot more. Thank you for your update Digittt. GLA
No Red, we don't :-)
Possibly, dhub apologies
Pingu, I've never had close to 4m. Don't know where you got that figure from? Not confusing me with JHFH are you? I'm certainly not a deramper either, just frustrated with the position we are at currently.
Someone clearly taking advantage of this drop. A 383k buy
Time will tell Dhub.
I can't see it going sub 6p again, but then again, I couldn't see it going below 9p.
Oh and thanks for your efforts Digitt
To be fair Pingu we all talk up/down to suit our own interests
Have added 120k more today so Gooo!! Hemo (cue pom poms visual)
More conversions incoming? Note all, I did get a call from PHC this morning. There was no clarification he could give ie between which way the IP licensing negotiations are going, but he did say that GlobalCo were severely slowed by COVID and that rolls through all of this still. They are, though, still keen and relationships are good...although that's all similar to what we've heard / know already, so nothing new.
Your view anything to do with you reducing your holding from 4m to 2.3m in the last week and now wanting a drop for some more cheap ones dhub?
The sea of red is only LSE designation, on low volume today around 60% are buys.
So either a big seller (possible with CLN in background) or just churn
I'm just seeing a sea of red B1ll, and yes I think this will drop below 6p again, unless we get a favourable RNS very very soon
Big sell off? 6p?
By the way, great post Hulver
Hulver
Agree with your reasoning and post in general, these type of negotiations are always more complicated particularly as we do not know at precisely what stage they are at.
Aspen
GLA
Picking up on JHFH’s comment earlier of the possibility of a JV or partnership, I do consider that a very reasonable possibility.
It seems that a position has been reached where the collaboration has resulted in a bi-specific antibody that both parties consider to be of clinical grade quality.
I am of the opinion that Globalco (after 3 years input) want to license it outright but would like (have expected) it now at a price towards the pre-clinical asset end of the drug value spectrum, whereas Vlad, understanding the product’s current status and future expectation, wants to receive a price towards the clinical asset end of the drug value spectrum.
So the ongoing negotiations are aimed at finding a way forward that each party considers equitable and workable. I considered the RNS simply as being early notification to shareholders before Easter and well in advance of the ‘previously reported deadline’ expectation that licensing discussions were and would be ongoing. In my view it was issued then to try avoid any shareholder panic or criticism, given that Hemo already knew that discussion were going to take further time, to reach a potentially more complex solution.
The various things we have seen going on in the background suggest that this is not a simple arrangement and any agreement may require certain conditions precedent being fulfilled, which will take time to put in place.
Intertwined are other collaborations with this Globalco and other globalcos, so I don’t consider that a take-over is likely (at this stage), but if Globalco does have longer term designs on Hemo would it not make sense for them to continue that relationship closely in a JV or partnership to clinical trials on CDX? And from a Hemo shareholder’s perspective I don’t think it would be that bad either, yes there is ongoing product risk through development but for a significantly greater long-term reward. All the time the value seems to be building. I'm holding my shares too.
Pingu - guess we would not need lawyers if contracts / leases / commercial deals / communications were unambiguous . we are all finding a pathway through this but hopefully we all end up where we hope to be. GLA
Cheers Chris
So basically as alluded I’ve taken to the formal RNS of the negotiations have begun indicates they want it - taking the option - as people want to see it referred.
Another RNS would be nice for the market it seems to provide this clarity but I think such additional clarification will come in the form of the deal being done or not.
I don’t see why they’d say they’re activating the option as such to then negotiate terms and then walk away unhappy. Entering negotiations is executing the option by default surely?
If people make investment decisions based on a BB then they won’t get very far.
I have my view of what will happen and why and a view on the overall intentions of what I think Vlad wants based on all the RNSs to date and the overall picture now at HEMO.
The fact is negotiations are ongoing and we will find out once they’re concluded.
Hopefully not too long til the action starts.
I think what you have said makes sense Pingu. The point which is being made though is that the exercising of the "option" is merely due confirmation that we are at stage 1 as you describe it. EL exercising the option, ONLY gives EL a period of exclusivity to agree a commercial deal with Hemo (nothing is guaranteed)- the "Option" as we all know is not the actual commercial deal - the deal could take 6 months and collapse and then as you rightly say Stage 2 where Hemo then have a right to agree commercial terms for themselves to move the product forward - which is why they tee'd up the finance, to both enable them to do that and illustrate and improve their negotiating position with EL/Global Co. Points which have been made many times. Stage 1 and stage 2 negotiations may well merge or cross over within the 6 months (if that's the stage we are in) and may well shape the outcome of Stage 2 if that is where we end up.
Stage 3 no one wants.
In summary, I believe it can be reported that an "option" has been exercised by a "Global co" and we then know what the real platform of the negotiation is (Stage 1 or Stage 2; 6 months or 3 months). If Stage 1 fails Stage 2 naturally comes into play.
The disssention here is in the opposing views about whether exercising an "option" (not a deal) can/should/needed to be reported pre a commercial deal and I see no reason why it could not. It is of material interest and the RNS have put dates (3 months) on "Option" exercising so the least that should be expected is a follow up RNS when the 3 months have expired. I appreciate there are opposing views on this. That said, it is good to have a couple of positive scenarios in the pipeline so they've got my vote as an investable business. GLA
No chance of buy out CJ, ORGS couldn’t afford us
Buy out apparently on the cards... that’s despite Vlad not selling.
Pingu, yes you have made some sensible assumptions, but assumptions are all they are.
Some folk will read these boards and will incorrectly assume that yours or other people's assumptions are fact.
I'm not selling any shares if E.L if don't take up the option, but some people's heads will pop off if they don't because they think these posts are fact.....more fool them.
Good luck all.
Come on Hemo!